Business Wire

SentryOne Introduces Database Monitoring Edition Targeted to Smaller Environments

7.2.2019 17:00:00 EET | Business Wire | Press release

Share

SentryOne launched SQL Sentry Essentials, a new edition of the company’s top-rated SQL Sentry database monitoring product that provides core monitoring capabilities for up to five database targets at $995 per targeted SQL Server instance.

SQL Sentry Essentials includes the most frequently used features for monitoring, diagnosing, and optimizing SQL Server performance. This new edition is ideal for small and medium companies as well as larger organizations that need to monitor specific data systems within their environment.

“SQL Sentry Essentials is a perfect choice when you need to deploy SQL Server performance management at a small scale, or if you need enterprise capabilities but aren’t ready to build the case for an investment in a larger database performance management solution,” said Jason Hall, SentryOne VP of Product Management. “This new edition gives you the crucial information you need to get to the root of your SQL Server performance problems.”

SentryOne introduced SQL Sentry Essentials to meet the industry need for a monitoring solution that provides powerful core monitoring capabilities but excludes advanced features valued by larger enterprises.

“Everyone needs to monitor their databases, but not everyone needs all the advanced features of our flagship product, SQL Sentry,” said Andy Mallon, SentryOne Product Manager. “We’ve distilled the feature list down to the most essential monitoring capabilities, now available as SQL Sentry Essentials. This new edition is a powerful, capable solution for companies who need to monitor up to five instances, all at a very attractive price.”

SQL Sentry Essentials includes five of the most frequently used SQL Sentry features, helping data pros view essential real-time performance metrics, identify high-impact queries that are slowing performance, use proactive notifications to prevent problems, analyze SQL Server blocking and deadlocks, and view Windows resource metrics.

SentryOne customer David Klee, Heraflux Technologies Founder and Chief Architect, said that one of the features included in SQL Sentry Essentials, the Performance Analysis Dashboard, gives actionable information that helps data pros quickly identify and address problems.

“Lots of other utilities provide 'pretty' dashboards that do not provide much meaning,” Klee said. “SentryOne gives you a dashboard that presents vital performance statistics. Anything unusual jumps out at you and helps you refine how you approach that server.”

SQL Sentry Essentials is priced at US$995 per license, which can be applied to one targeted SQL Server instance, plus US$199 for annual maintenance (first year required). Subscription pricing is available at US$50 monthly (annual commitment required).

For more information, visit sentryone.com/sqlsentry-essentials.

About SentryOne
SentryOne empowers Microsoft data professionals to build, test, document, and monitor SQL Server, Azure SQL Database, and the Microsoft Data Platform. We help companies accelerate performance across the data lifecycle with unmatched scalability, best-in-industry customer support, and the most powerful data performance management capabilities available. Our team includes a core group of Microsoft MVPs and staff located in Charlotte, NC, Jacksonville, FL, Salem, NH, and Dublin, Ireland. Learn more at SentryOne.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Megan Keller
Communications Manager
media@sentryone.com

Erik Arvidson
Matter for SentryOne
978-518-4542
sentryone@matternow.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 10:00:00 EEST | Press release

Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and support, the Westcoast partnership helps cut the ‘meeting tax’, reducing set‑up friction and getting meetings started on time. The announc

Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 10:00:00 EEST | Press release

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the freedom to book their own trips without getting bogged down in manual approvals. Navan gives t

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 10:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic

Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 09:00:00 EEST | Press release

Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled the world’s first S250-FIT installation, developed in collaboration with Leo Cancer Care. The system was fully installed within a stan

CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results11.5.2026 08:10:00 EEST | Press release

Business Updates section, the first bullet of release dated April 23, 2026, at 10:04 p.m. PT/April 24, 2026, at 1:04 a.m. ET should read: In October 2025, Samsung Bioepis entered into a private label partnership with Cordavis for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1. The updated release reads: SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye